Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 3, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing changes in their interests in the company's Ordinary Shares and American Depository Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory notification regarding director share allocations and does not contain financial performance data.
Material Changes
On December 31, 2007, the company's Non-Executive Directors were provisionally allocated awards over Ordinary Shares and ADSs through the Annual Re-investment of Dividends paid throughout 2007. These allocations were informed to the company and directors on January 2, 2008.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance filing under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- The filing details specific share allocations for Non-Executive Directors resulting from dividend reinvestment in 2007.
- Allocations were made in both Ordinary Shares (average price GBP 12.8433) and ADSs (average price USD 50.82).
- Directors receiving allocations include Sir Ian Prosser, Sir Christopher Gent, Dr Stephanie Burns, Mr Lawrence Culp, Sir Crispin Davis, Sir Deryck Maughan, Dr Daniel Podolsky, Dr Ronaldo Schmitz, Mr Tom de Swaan, and Sir Robert Wilson.
- Prof Sir Roy Anderson received no allocation in this specific notification.
- No financial performance metrics are disclosed in this document.